By Fineline Cube 
China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for Carvykti (ciltacabtagene autoleucel) at the ASCO 2025 Annual Meeting. The data revealed unprecedented long-term outcomes in patients with relapsed or refractory multiple myeloma (RRMM).
Long-Term Outcomes
The results showed that 33% (32/97) of treated patients remained progression-free for ≥5 years after a single infusion, with no subsequent myeloma therapy required. The median overall survival (OS) reached 60.7 months (95% CI: 41.9–Not Reached), demonstrating a durable clinical benefit. Additionally, MRD-negative patients showed no signs of relapse in annual PET/CT scans over 5 years.
Safety Profile
In terms of safety, no new cases of movement disorders or neurocognitive toxicity were observed, although two new secondary primary malignancies (both solid tumors) were reported.
CARTITUDE-4 Study
Furthermore, the CARTITUDE-4 study confirmed consistent progression-free survival (PFS) and OS benefits across high-risk subgroups, including patients with adverse cytogenetic profiles, extramedullary disease (EMD), and heavy prior treatment exposure.-Fineline Info & Tech